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Positron emission tomography (PET)
A B S T R A C T
Earlier post-mortem histological and autoradiographic studies have indicated a reduction of cell numbers
in the locus coeruleus (LC) and a corresponding decrease in norepinephrine transporter (NET) in brains
obtained fromAlzheimer’s disease (AD) patients as compared to age-matched healthy controls. In order to
test thehypothesis that the regional decreaseofNET is a disease speciﬁcbiomarker inADandas such, it can
be used in PET imaging studies for diagnostic considerations, regional differences in the density of NET in
various anatomical structures were measured in whole hemisphere human brain slices obtained from AD
patients and age-matched control subjects in a series of autoradiographic experiments using the novel
selective PET radioligand for NET (S,S)-[18F]FMeNER-D2. (S,S)-[
18F]FMeNER-D2 appears to be a useful
imaging biomarker for quantifying the density of NET in various brain structures, including the LC and the
thalamuswherein thehighestdensities are found inphysiological conditions. InADsigniﬁcantdecreases of
NET densities can be demonstrated with the radioligand in both structures as compared to age-matched
controls. The decreases in AD correlatewith the progress of thedisease as indicated by Braak grades. As the
sizeof theLC isbelowthespatial resolutionof thePET scanners, but thesizeof the thalamuscanbedetected
with appropriate spatial accuracy in advanced scanners, the present ﬁndings conﬁrm our earlier
observationswith PET that the in vivo imaging of NETwith (S,S)-[18F]FMeNER-D2 in the thalamus is viable.
Nevertheless, further studies are warranted to assess the usefulness of such an imaging approach for the
early detection of changes in thalamicNETdensities as a disease-speciﬁc biomarker and thepossible use of
(S,S)-[18F]FMeNER-D2 as a molecular imaging biomarker in AD.
 2010 Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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journa l homepage: www.e lsev ier .com/ locate /neuint1. Introduction
One of the major monamine neurotransmitters is norepinephr-
ine (NE) or, with other term, noradrenalin. The major source of NE
in the brain is the LC which is located in the rostral pons.
Noradrenergic terminals in the brain are widespread and LC
neurons project to the cerebral cortex, thalamus, cerebellum and
neurons in brain stem nuclei (Smith et al., 2006). The NE system
plays a role in various CNS functions including brain maturation,
autonomic regulation processes, stress related actions, attention
and memory functions. The system has been identiﬁed as a major
biological underpinning of certain personality traits, as well. The
dys-regulation and pathology of the NE system has been identiﬁed* Corresponding author.
E-mail address: balazs.gulyas@ki.se (B. Gulya´s).
0197-0186/$ – see front matter  2010 Elsevier Ltd. All rights reserved.
doi:10.1016/j.neuint.2010.03.001in several CNS pathologies, including neurodegenerative diseases,
ADHD, schizophrenia and depression.
The norepinephrine transporter (NET), similarly to other
transporter in the pre-synaptic cell membrane, plays a major role
in the regulation of NE related actions at cellular levels (Schroeter
et al., 2000; Sanders et al., 2005). As NET is responsible for the re-
uptake of NE and, by this way, for the intra-synaptic NE levels, it is
the target of several therapeutic drug actions as well as that of
abused drugs. Furthermore, the concentration of the released NE in
the extrasynaptic space (Vizi, 2000) is also regulated by NET.
The quest for identifying appropriate early disease biomarkers
in Alzheimer’s disease (AD) has been in the forefront of biomarker
research in recent years. Amyloid and insoluble Ab peptides have
been identiﬁed as disease biomarkers (Andreasen and Zetterberg,
2008; Hampel et al., 2008; Svedberg et al., 2009) for which
molecular imaging biomarkers have also been developed (Klunk
et al., 2004; Nordberg, 2007, 2008; Cai et al., 2007). Activated
Fig. 1. Structure of (S,S)-[18F]FMeNER-D2 (A) and reboxetine (B).
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(PBR/TSPO) (Banati, 2002; Venneti et al., 2006; Chen and Guilarte,
2008; Gavish et al., 1999) are other evident candidates, as are
activated astrocytes and the MAO-B system (Schwab and McGeer,
2008; Fuller et al., 2009; Rodrı´guez et al., 2009; Razifar et al., 2006;
Johansson et al., 2007). For these systems, molecular imaging
biomarkers are already available (Kumlien et al., 1995; Reutens,
2000; Kassiou et al., 2005; Dolle´ et al., 2009; Gulya´s et al., 2009;
Fowler et al., 1995). Recently other target systems are also
considered, including the NE system.
In AD a profound reduction of LC cell numbers by averaged 50–
70% (compared to age-matched healthy controls) and a corre-
sponding decrease in NET have consistently been documented by
numerous post-mortem studies (Tejani-Butt et al., 1993; Lyness
et al., 2003; Zarow et al., 2003). For this reason, the degeneration of
LC in AD may bear important implications for both the early
diagnosis and the treatment of the disease (Haglund et al., 2006) as
it may serve as a disease biomarker for which molecular imaging
biomarkers, as diagnostic agents, can be developed. Until today,
only sporadic data have been available on the degeneration of the
terminal ﬁelds of LC neurons (e.g. in the thalamus, the amygdala
and the cortex) or about the existence of compensatory mechan-
isms, e.g. up-regulation of NET, in the LC and the aforementioned
target regions (e.g. Hoogendijk et al., 1999; Szot et al., 2006). On the
other hand, the degeneration of the LC has been correlatedwith the
potentiation of amyloid-induced cortical inﬂammation in AD
(Heneka et al., 2002, 2006; Kalinin et al., 2007) as well as
behavioural changes (aggressive behaviour, cognitive impairment)
in dementias (Matthews et al., 2002).
Consequently, early changes in brain NE and NET levels can
serve as disease biomarkers in AD and other neurodegenerative
diseases. NET-rich regions in the human brain may therefore serve
as a target for diagnostic imaging, with special regard to early
diagnosis of AD using molecular imaging techniques, including
positron emission tomography (PET). Naturally, this would also
require adequate molecular imaging biomarkers.
For long there have been two major obstacles in the way of a
routine PET diagnostic approach using the imaging of NET in the
human brain for early AD diagnosis: (i) the size of the LC in the
human brain is below the spatial resolution of the currently used
diagnostic PET scanners (usually between 3 and 6 mm) (German
et al., 1988), and (ii) the lack of optimal diagnostic PET ligands for
imaging the NET system.
Further to initial studies with carbon-11 labelled MeNER
analogues (Wilson et al., 2003), with the introduction of the
selective NET ligand (S,S)-[18F]FMeNER-D2 (Schou et al., 2004,
2005) an appropriate PET ligand has become available for the
imaging community. Early PET studies on non-human primates
and on humans have indeed demonstrated the usefulness of the
novel ligand in the in vivo exploration of the NET system (Schou
et al., 2004; Arakawa et al., 2008; Takano et al., 2008a,b,c; Takano
et al., 2009a,b), as did studies with the tritiated analogue in in vitro
experiments (Ghose et al., 2005). However, these early PET studies
have also called our attention to the second aforementioned issue,
namely that the size of the LC, is not an appropriate anatomical
target for routine imaging studies of the NET system in humans.
Alternatively, other anatomical structures with relatively high NET
densities and volumes appropriate for diagnostic PET scanners
may serve as perspective target structures for routine imaging
procedures on early AD diagnosis in the future.
The main objective of the present investigation was threefold:
(i) To explore the possible changes in NET densities in AD brains in
comparison with age-matched control brains with the help of the
prospective NET radioligand (S,S)-[18F]FMeNER-D2. (ii) To clarify
whether there is a demonstrable reduction in NET in the thalamus,
the prime projection structure of LC, whether this reduction goesparallel with that in the LC, and, consequently, the thalamus could
also serve as a target region for PET imaging of NET in AD patients.
(iii) To assess the possible use of (S,S)-[18F]FMeNER-D2 as a
molecular imaging biomarker in AD in the future.
2. Experimental procedures
2.1. Radiochemistry
(S,S)-[18F]FMeNER-D2 (Fig. 1A), a radiolabelled analogue of reboxetine (2-(2-
ethoxyphenoxy)-phenyl-methyl)morpholine (Fig. 1B), was prepared as described in
detail elsewhere (Schou et al., 2004). Radiochemical purity was higher than 99%.
The speciﬁc radioactivity was higher than 176 GBq/mmol.
2.2. Brain tissue
2.2.1. Whole hemisphere brain slices
Whole hemisphere brain sections from 10 AD cases, covering various Braak
stages, and 10 age-matched, healthy controls have been investigated.
Human brains without pathology were obtained from the National Institute of
Forensic Medicine, Karolinska Institute, Stockholm (n = 10). Ethical permission was
obtained from the relevant Research Ethics Committee (Dnr. 01-161). The brains
had been removed during forensic autopsy, were ‘‘freshly frozen’’ andwere handled
in a manner similar to that described previously (Hall et al., 1998; Varna¨s et al.,
2004). The deceased persons’ age varied between 32 and 75 y, the causes of death
were suicide, cardiovascular, and pulmonary embolism, the post-mortem time
interval was between 2 and 23 h. The sectioning took place on a Leica cryomacrocut
system. The resulting slices were horizontal slices of 100mm thickness.
Ten brains from Alzheimer patients were obtained from the Alzheimer Research
Group of the Albert Szent-Gyo¨rgyi Medical and Health Science Center, University of
Szeged. Ethical permissionwas obtained from the Research Ethics Committee of the
University of Szeged (1895/2004). The post-mortem time interval was between 2.5
and 5.0 h. The patients’ age was between 54 and 98 y, and the collection covered
Braak stages between 0.5 and 5. The brains had been removed during clinical
autopsy and were handled similarly to that described above. The sectioning took
place on a Leica cryomacrocut system. The resulting slice thickness was 100mm.
Various coronal sections intersecting the parietal and temporal lobes, the basal
ganglia and the hippocampus were used for the measurements.
The stipulation of the experiments was due to the autopsy and sectioning
technique: The ten control brains were harvested in a dedicated manner for a post-
mortem human brain bank and, consequently, they were sectioned horizontally
and the LC is visible on the sections. The AD brains were obtained from clinical
autopsies and coronal sections were made. The brainstem was not a part of the
original slabs, and there is no LC on the coronal sections.
2.2.2. Brain blocks
Brain blocks (approximately 1 cm3 in volume each) from 5 Alzheimer patients
and 5 age-matched controls were obtained from the Netherlands Brain Bank
(protocol number: 2007/526). In each case, from one hemisphere fresh frozen brain
blocks were obtained from the following anatomical regions: brainstem containing
the LC, thalamus, hippocampus, parietal and temporal lobes. From each block, slices
of 20mm thickness were cut and used for the autoradiography (ARG) studies. From
the same brains’ other hemisphere formaldehyde ﬁxed (4%) and parafﬁn-embedded
brain blocks were obtained from identical anatomical regions and 6mm thick slices
sections were used for immunohistochemical studies.
2.3. In vitro autoradiography
2.3.1. Whole hemisphere brain slices
Experimental procedures followed those described in Schou et al. (2005), with
the exception of incubation time, which was shortened due to the use of a high
sensitivity phosphorimager. The whole hemisphere sections were incubated for
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buffer (50 mM, pH 7.4) containing sodium chloride (300 mM), potassium chloride
(5 mM), and ascorbic acid (0.1%, w/v). The sections were then washed 3  5 min in
the same buffer (at RT), then brieﬂy dipped in ice cold distilled water. The readings
were made in a Fujiﬁlm BAS-5000 phosphorimager and digitized using a Fujiﬁlm IP
Eraser 3. Standards were prepared by serial dilution of the radioligand stock
solution in assay buffer. Aliquots (2mL) of the standards were spotted onto
polyethylene-backed absorbent paper (BenchGuard), allowed to dry, scanned and
digitized in the phosphorimager parallel with the tissue scans. From the known
speciﬁc activity of the radioligand, the corresponding concentration (fmol) of
radioligandwas calculated and the correlation between the amount of the standard
(kBq) and the phosphorimager signal was established. The speciﬁc binding values
were calculated by using the total binding values and the non-speciﬁc binding
values, determined in the excess of nisoxetine (10mM).
2.3.2. Binding assay on slices from small brain blocks
Before application of the autoradiographic technique to the AD tissue, using
brain blocks (hippocampus) from the control material we identiﬁed optimal
conditions for labeling of NET with (S,S)-[18F]FMeNER-D2 for various parameters,
including optimal ligand concentration, temperature and incubation time, in a
series of saturation experiments with increasing ligand concentrations, incubation
times and temperatures.
LC consecutive tissue sections (20 mm) in triplicates were used. In order to
determine the KD value and the optimal ligand concentration, ﬁrst saturation of (S,S)-
[18F]FMeNER-D2 binding was performed at 22 8C (RT) and at 37 8C. Tissues were
incubated with (S,S)-[18F]FMeNER-D2 at ﬁve concentrations in the range between
0.02 and 120 nM in Tris buffer (pH 7.4) for 90 min. Parallel incubations were carried
outwith consecutive sections in the same incubationmediumwith10mMnisoxetine
added. The sectionswere thenwashed twice with the same buffer and ﬁnally dipped
intodistilledwateronce.Afterdrying, sectionswere exposed to thephosphor imaging
plate for 3 h. The Fujiﬁlm IP Eraser 3 was used to erase the images from the plates in
the image-reading unit of the Phosphor Imager (Fujiﬁlm BAS-5000). Optical densities
were digitized and analyzed using an image analysis program MultiGauge V3.0.
For quantiﬁcation, individual calibration standards were prepared for each set of
the brain sections exposed to the same imaging plate. The standards were 20mL
drops of (S,S)-[18F]FMeNER-D2 from the incubation solution (solutions with 3
different concentrations [0.0001, 0.004 and 60 MBq/mL] were used) placed on a
thin, absorbent paper and exposed simultaneously with the brain sections.
Knowing the concentration and the volume of the standard sample (the drop with
the optical density closest to the section’s optical densities was chosen for
calculations), the amount of substance expressed in fmolwas calculated (Johnstro¨m
and Davenport, 2005). The total counts over the standard, measured by the
phosphor imaging system, allowed the calculation of calibration factor in counts per
fmol. Using the GraphPad Prism software and knowing number of counts per square
millimeter for each ROI and calibration factor, we converted it to fmol per square
millimeter and then to fmol per cubic millimeter. Similarly, curves obtained with
GraphPad Prism were used to determine KD and Bmax values.
In order to optimise incubation times, the brain slices were incubated with (S,S)-
[18F]FMeNER-D2 at the concentration of 0.4 MBq/mL (which corresponded to
3.68 nM) for different incubation times (2, 5, 20, 60, 120 and 180 min) at RT as well
as at 37 8C. Parallel incubations were carried out with 10mM nisoxetine added. In
another series, this optimal ligand concentration was replaced by a sub-optimal
ligand concentration corresponding to 0.04 MBq/mL, in order to test concentration
dependence of the signal in the key structures. Equilibrium was achieved at both
temperature conditions, although faster at the 37 8C (after approximately 45 min)
than at RT (after approximately 120 min).
In the ﬁrst binding assay series, using optimised experimental conditions, LC and
thalamus from 5 controls and 5 AD brains were investigated. Tissues were
incubated with (S,S)-[18F]FMeNER-D2 at the concentration of 0.4 MBq/mL
(3.68 nM) for 120 min at RT. 10mM nisoxetine was used as a blocker in theFig. 2. Toluidine blue staining of NET containing neurons in the LC of control (A) and A
longitudinal axis of the LC in both cases. Origin of tissue: Netherlands Brain Bank.)parallel sections. Speciﬁc binding was obtained after subtraction of non-speciﬁc
binding from total binding.
2.4. Histochemistry and immunohistochemistry
Parafﬁn-embedded tissue sections were deparafﬁnated, hydrated and stained in a
0.1% toluidine blue solution containing 0.1% boric acic for 1 min. After rinsing in
distilled water for a few seconds, the sections were dehydrated quickly through 95%
and two-changes of 100% ethanol, cleared in xylene for 2 3min, and coverslipped in
DPX mounting medium. For the demonstration of the presence of tau proteins in
affectedneurons aswell as amyloid plaques and reactive astrocytes in the samebrains
from which the fresh frozen brain slices for autoradiographic experiments were
prepared, we used (1) AT8 monoclonal antibodies with diaminobenzidine (DAB)
enhancer for tau protein recognition, (2) GFAPmonoclonal antibody or (3) a combina-
tion of tau or GFAP signal (with ﬂuorescence enhancement) and thioﬂavine S amyloid
plaque labeling Kele´nyi (1967) on parafﬁn-embedded brain sections (Amsterdam
material). Immunohistochemistry was performed according to Kortvely et al. (2003).
2.4.1. Tissue preparation for immunohistochemistry
The parafﬁn-embedded sections were ﬁxed in 0.1 M TBS (Tris-buffered saline;
pH 7.5) containing 4% formaldehyde for 10 min and washed for 3 5 min in 0.1 M
TBS at room temperature (RT). The parafﬁn-embedded sections were incubated in
0.05 M Tris–HCl solution (pH 7.6) containing 0.1% trypsin and 0.1% CaCl2 for 15 min
in a humidiﬁed chamber at 37 8C. After blocking the endogenous peroxidase in 1%
H2O2 for 15 min at RT, the sectionswerewashed for 3 5 min in 0.1 MTBS at RT. The
tissue sections were permeabilized and the background binding of the antibodies
was reduced in a blocking solution (0.1 M TBS solution containing 5% NGS (normal
goat serum), 1% BSA (bovine serum albumin), 0.05% Triton X-100) for 30 min at
37 8C. Sections were covered with a solution containing mouse anti-tau primary
antibody (AT-8; Pierce) diluted to 1:1000 in the blocking solution at 4 8C overnight,
then washed for 4 10 min in 0.1 TBS at RT.
2.4.2. DAB immunohistochemistry
The sections were treated with an anti-mouse IgG secondary antibody diluted
(1:200) in a blocking solution (where Triton X-100 was omitted) for 5 h at RT. After
several washes (4 10min), biotinylated streptavidin-peroxidase tertiary antibody
(1:200) in a blocking solution (without Triton X-100) was applied to the sections
overnightat4 8C.Thesectionswerewashedagain in0.1 MTBS for410minatRTand
processed for peroxidase enzymehistochemistry. The sectionswere pre-incubated in
ﬁltered 0.1 M TBS solution containing 0.5 mg/mL 3,30-diaminobenzidine (DAB) for
20 min at RT, and thendeveloped in the same solution but also containing 0.01%H2O2
for 20 min at RT. The sectionswerewashed for3 5 min in0.1 MTBS and thendipped
into distilled water for a few seconds. The cell nuclei were stained in 0.1% toluidine
solution for 1 min, washed in distilled water for 1 min, dehydrated in a series of
ethanol solutions, covered with DPX (distrene plasticizer xylene) and cover-slipped.
2.4.3. Tau and GFAP immunohistochemistry (Alexa)/amyloid staining with Thioﬂavin S
The sections were treated with Alexa 568-conjugated anti-mouse IgG secondary
antibody diluted (1:1000, InvitrogenTM) in a blocking solution (where Triton X-100
was omitted) for 5 h at RT. After several washes (4 10 min) in 0.1 M TBS the cell
nuclei were stained in 0.1 M TBS containing 1 mg/mL polyvinylpyrrolidine and
0.5mL/mL Hoechst 33258 dye (Hoechst). The sections were then rinsed for 2
5 min in 0.1 M TBS containing 1 mg/mL polyvinylpyrrolidine solution and
processed for amyloid plaque staining. The sections were stained with Mayer
hematoxylin solution (100 mg hematoxylin, 20 mg Na-iodate, 5 g aluminum
potassium sulfate, 5 g trichloroacetaldehyde nitrate, 100 mg citric acid) for 5 min at
RT. After washing the sections in ﬁltered tap water for 5 min, they were stained in
1 mg/100 mL thioﬂavin S solution. The sections were ﬁnally washed for 5 min in
distilled water, air-dried overnight, covered with Vectashield and cover-slipped.D (B) brains. (Magniﬁcation made with a 5 objective; sections made across the
Fig. 3. Tau andGFAP immunoreactivity around the amyloid plaques in thehippocampi of parafﬁn-embedded sections of control and ADbrains (A, B). The non-demented, control
brain (Amsterdammaterial 00-142)was staged as Braak1,while the Alzheimer’s diseased brain (02-080)was diagnosed as Braak5. The hippocampus in the control brain didnot
show tau immunopositivity (A), while the hippocampus from the AD sample displayed a large number of tau positive neurons (B). Scale bars for A and B: 200mm. Detection of
tau (C–F andH) andGFAP (G) immunoreactivities around the amyloid plaques in the gyrus temporalis and the hippocampus of ADbrains. The sampleswere from the Amsterdam
material: 05-071, gyrus temporalis, Braak 6 (C, D, F); 02-080, hippocampus, Braak 5 (E); 05-012, gyrus temporalis, Braak 6 (G). Tau positive neurons (arrows) in the gyrus
temporalis (C, D, F) and the hippocampus (E)were detected byDAB staining (seeMaterials andMethods). A number of GFAP positive astrocytes (G) and tau positive neurons (H)
(red immunoﬂuorescence) could be seen around the amyloid plaques stained with thioﬂavin S (green ﬂuorescence) in the hippocampus. Scale bars for C–H: 100mm.
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3.1. Histology. Demonstration of cell loss in the LC
Cell densities in the LC were demonstrated using toluidine blue
stain. The stain indicated a signiﬁcant loss of LC neurons in the AD
sections as compared to the sections obtained from age-matched
control brains (Fig. 2).
3.2. Immunohistochemical veriﬁcation of presence of Alzheimer
pathology in AD samples
Immunohistochemical studies of AD brains, in contrast to age-
matched control brains, indicated a clear-cut signal for both the
anti-tau/DAB stain and the double staining with tau antibody
(Alexa 568 detection) and thioﬂavine S stain, conﬁrming the
presence of amyloid beta and tau pathology. GFAP positive reactive
astrocytes were also present around the amyloid plaques. In the
control brains therewas no positive signal for either stain (data not
shown). In the AD brains both stains showed positive signals in
various brain structures (Fig. 3).
3.3. Autoradiography in whole hemisphere brain sections: regional
binding parameters
Visual examples from control brains are shown in Fig. 4. As
shown on the whole hemisphere horizontal slices at the levels ofFig. 4. Control brain (70 ymale), horizontal slices, ARGwith (S,S)-[18F]FMeNER-D2. A, C, E a
hemisphere slices at the level of the LC (A and B) and the thalamus (C and D). E and Fthe LC (panels A, B, E, F) and the thalamus (panels C, D, G, H), there is
a high uptake of (S,S)-[18F]FMeNER-D2 in the LC which can be
clearly blocked by an excess of nisoxetine. Also, there is a clear
uptake in the thalamus, which is signiﬁcantly reduced by an excess
of nisoxetine. As shown in the images, the uptake of the
radioligand was not homogeneous in the cortex and the various
sub-cortical structures. The comparison between control and AD
brains indicated relatively higher ligand uptake in cortical
structures in AD brains, in line with earlier publications on
eventual compensatory increases in NET densities in the projection
regions of LC in AD (Fig. 5).
The quantitative analysis of the samples indicated that in
control brains the highest mean speciﬁc binding was in the LC
(34.8 fmol/mm3), followed by approximately ten times lower
binding in the thalamus (4.2 fmol/mm3). This was followed by the
lateral geniculate nucleus (LGN; 3.8 fmol/mm3), the frontal lobe
and putamen (3.6 fmol/mm3), the occipital, temporal and parietal
lobes (3.3, 2.5 and 0.6 fmol/mm3), respectively, and other sub-
cortical structures (Table 1).
In the AD brains the measuring of regional binding in all
identical structures present in the horizontal slices (control
material was not possible due to technical limitations coronal
sectioning). Despite this technical limitation, the binding values
in the comparable structures show in some cases marked
differences between control and AD brains, but the effect’s
signiﬁcance cannot be assessed due to the small sample size
(Table 1).ndG: baseline condition, B, D, F andH: blockingwith 10mMnisoxetine. A–D:whole
: LC magniﬁed. G and H: Thalamus magniﬁed.
Fig. 5.Whole hemisphere autoradiography with (S,S)-[18F]FMeNER-D2 in baseline condition in an age matched control brain (horizontal slices, 33 y male) (A: baseline [total
binding], B: blocking with 10mM nisoxetine [non-speciﬁc binding]) and an AD brain (coronal slices, 50 y old female, Braak 2/3) (C: baseline [total binding], D: blocking with
10 mM nisoxetine [non-speciﬁc binding], E: ‘total binding – non-speciﬁc binding’ subtraction image, showing speciﬁc binding).
Table 1
Mean speciﬁc binding values (Bmax; in fmol/mm
3, blocking with nisoxetine) in various brain structures obtained from whole hemisphere AD and control brain sections
(n=number of brains). The brain samples belong to those obtained by the Karolinska Institute (controls, total n=10) and the University of Szeged (AD, total n=10). Due to the
differences in sampling and sectioning, the control brains (sectioned coronally) containmore structures than the AD brains (obtained frompathology obductions after routine
macroscopic neurohistological examinations and sectioned horizontally; consequently, a number of structures are not present).
Brains Control AD
Structures Bmax SEM n Bmax SEM n
LC 34.8 3.0 7 n.a. – –
Thalamus 4.2 1.5 8 1.7 1.9 3
LGN 3.8 – 1 n.a. – –
Frontal 3.6 1.0 9 0.5 – 1
Putamen 3.6 1.5 8 n.a. – –
Temporal 2.5 1.0 10 2.8 2.1 3
Parietal 0.6 2.1 2 4.0 1.3 2
Occipital 3.3 1.9 4 n.a. – –
Hippocampus 1.6 0.8 3 0.6 – 1
Cerebellum 1.0 0.5 8 n.a. – –
White matter 0.9 0.7 10 1.4 1.3 3
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Analysis of the quantitative assays using small brain block slices
in triplicates at RT resulted in the following values for the binding
parameters: KD = 3.6 nM and Bmax = 84.3 fmol/mm
3.
Using both radioactivity concentrations (0.4 and 0.04 mBq/mL),
there was a marked difference in speciﬁc binding between AD and
control brains in the LC and thalamuswhereas there appeared to be
no marked difference in other structures (hippocampus, temporal,
parietal lobes). In the thalamus this marked difference at
0.04 MBq/mL did not reach signiﬁcance (p = 0.1711), at 0.4 MBq/
mL radioactivity concentrations the difference between AD and
age-matched control brains was signiﬁcant (p = 0.0353) (Fig. 6).
3.5. Correlation between Braak grades and binding
Using 0.4 MBq/mL radioactivity concentration in the autora-
diographic experiments, we found a signiﬁcant negative correla-
tion between Braak grades and speciﬁc binding in both the LC and
the thalamus in the 20 mm thick brain slices obtained from the
small brain blocks including control (Braak 0–1) and AD (Braak 2–
6) material (‘‘Amsterdam brains’’) (Fig. 7). Due to the low r2 value,
however, this signiﬁcant correlation should be considered as a
preliminary observation which warrants further experiments to
assess the robustness of the correlation.
4. Discussion
Norepinephrine (NE) is one of the major monoamine neuro-
transmitters in the primate brain. Noradrenergic neurons in thehumanbrain are predominantly located in the LC, but other regions,
including the lateral tegmental areas, also contain cells producing
norepinephrine. The axons of these noradrenergic neurons reach
target neurons in various brain regions, including the thalamus, the
amygdala, the cingulate cortex, hypothalamus and hippocampus,
and the striatum, as well as cells in the spinal cord.
The norepinephrine transporter (NET), a membrane glycopro-
tein with 12 membrane-spanning domains, is the protein
regulating the re-uptake of NE from the synapse. NET is an
important target site for several CNS drugs, including antidepres-
sants, as well as drugs of abuse. Using autoradiographic techniques
with labelled NET ligands, such as [3H]nisoxetine, it has been
demonstrated that NET concentrations in the rodent brain are
highest in the LC, followed by the dorsal raphe nuclei (Ordway
et al., 1997). Other brain regions, rich in NET, are those which have
been identiﬁed as the main target regions of NE neurons.
Changes in NET densitymay be result of genetic polymorphism,
neurological and psychiatric diseases, physiological ageing or the
pharmacological effects of therapeutic or abused drugs (Klimek
et al., 1997; Tellioglu and Robertson, 2001). Due to its early
decrease in neurodegenerative diseases, including AD, NET appears
to be a useful biomarker of disease. The present investigation
focused predominantly on this issue, namely, what the quantita-
tive change of NET density is in the various brain structures in AD
and to what extent these changes correlate with disease
progression. Furthermore, the question that which of the various
structures in the human brain, rich in NET in healthy subjects but
loosing NET in AD, can be used as prospective target regions in PET
studies using (S,S)-[18F]FMeNER-D2 as an imaging biomarker, was
also tackled, with special regard to the possible role of the
Fig. 6. (A) Speciﬁc binding (fmol/mm3) in the LC in AD (black column) and age.
Matched control (white column) brains. The difference in the LC between AD and
control brains was signiﬁcant. Results obtained with 0.4 MBq/mL ligand
concentration and nisoxetine as the blocker. Errors bars indicate SEM, signiﬁcant
differences (p < 0.05) between average values are indicated by asterisk. (B) Speciﬁc
binding (fmol/mm3) in the thalamus, parietal and temporal lobes and the
hippocampus in AD (black columns) and age-matched control (white columns)
brains. Results obtained with 0.4 MBq/mL ligand concentration and nisoxetine as
the blocker. Errors bars indicate SEM, signiﬁcant differences (p < 0.05) between
average values are indicated by asterisk. The difference in the thalamus between AD
and control brains was signiﬁcant (p < 0.05). Please note the scaling difference
between the previous and present ﬁgures.
Fig. 7. Correlation between Braak grades and speciﬁc binding (fmol/mm3) in the LC
(A) and the thalamus (B). LC: slope: 5.607  2.175, r2 = 0.4537, p = 0.0327
(signiﬁcant). Thalamus: slope: 0.4415  0.1661, r2 = 0. 4688, p = 0.0289 (signiﬁcant).
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investigation did not aim at exploring in detail various important
corollaries of the decrease of NET in LC and other brain structures,
including the compensatory NE increase due to the loss of NET.
4.1. Methodological considerations
In the present experiments we have used two autoradiographic
approaches, each having respective advantages over the other, but
also stipulations. Themain advantage of whole hemisphere human
autoradiography is that it displays receptor distributions in whole
brain sections, thereby the regional distribution patterns can be
studied both quantitatively and qualitatively. In addition to a
unique technical background and expertise, this requires, however,
huge amounts of radioligands and imaging plates, i.e. due to
technical and ﬁnancial stipulations the technique should be used
‘‘economically’’. Autoradiography assays in human brain slices,
obtained from smaller blocks, require relatively less radioligandand can, therefore, be used more ‘‘economically’’ for quantiﬁcation
studies of ligand binding. But it has serious limitations, namely
that only limited anatomical structures in the brain can be
visualised. The brain slices used for the two techniques differ in
thickness as for whole hemisphere autoradiography the slice
thickness is usually around 100 mm, whereas it is only between 12
and 30 mm for small slice studies. This fact has consequences
regarding the concentration of the radioligand as well as the
quantiﬁcation of the binding values.
Keeping in mind these considerations we resorted to small
brain slice autoradiography for establishing optimised experi-
mental conditions and determining some of the basic binding
parameters of the ligand as well as to assess the concentration
dependency of the binding. On the other hand, we used whole
hemisphere autoradiography with a ‘‘one-point condition ap-
proach’’ to qualitatively and quantitatively explore the distribution
and binding of the radioligand. The binding assay on the 20 mm
thick small block brain slices established an optimal ligand
concentration (0.4 MBq/mL), but it has also shown that lower,
‘‘sub-optimal’’ concentrations, such as 0.04 MBq/mL may also
mirror the NET distribution in the brain faithfully. Keeping in mind
this fact and the differences in ligand uptake between thin and
thick slices (Varna¨s, 2005), the 0.02 MBq/mL concentrations in the
‘‘one-point condition approach’’ should faithfully represent the
transporter densities in various brain regions at the given
concentration.
In the autoradiography literature binding data are usually
normalised tomg tissue (as, for instance, in a former publication by
our group: Gulya´s et al., 2009) or to mg protein (as, for instance, in
Tejani-Butt et al., 1993; Ordway et al., 1997; Klimek et al., 1997). In
the present study, with an eye on avoiding compensation for
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volume tissue (fmol/mm3) due to that fact that preliminary
histological studies indicated a signiﬁcant loss of cells in LC.
4.2. NET distribution in normal brains
The present ﬁndings support earlier observations by other
studies, using autoradiographic measurements on post-mortem
human brain tissue. Ordway et al. (1997), using [3H]nisoxetine,
demonstrated high NET densities in the LC and the dorsal raphe
nuclei, the binding varying between 97.7 and 299.8 fmol/mg
protein in the dorsal raphe, between 75 and 101 fmol/mg protein
in the median raphe nuclei, and between 78 and 293 in the LC. In
the LC and the raphe nuclei Klimek et al. (1997), also using
[3H]nisoxetine, have shown binding values in the range of 150–
200 fmol/mg protein in control subjects, and markedly reduced
values in depressive patients. In the case of the caudal LC the
reduction in binding values was signiﬁcant. These observations
have been supported by human autoradiographic data using (S,S)-
[18F]FMeNER-D2 (Schou et al., 2005). In the non-human primate
brain, using [3H]nisoxetine, Smith et al. (2006) found the highest
binding values in the LC (219.63 fmol/mg wet weight tissue)
followed by the sub-coeruleus nucleus and the raphe. In vivo PET
measurements yielded further support to this regional distribution
pattern, using (S,S)-[18F]FMeNER-D2 in both non-human primates
(Schou et al., 2004; Seneca et al., 2006) and humans (Takano et al.,
2008a,b,c).
In the present experiments wemeasured speciﬁc binding in the
presence of an excess of nisoxetine and expressed it in fmol/mm3
of tissue. NET density in the LC is approximately an order of
magnitude higher (between 35 and 40 fmol/mm3) than NET
densities in the thalamus, the LGN, the basal ganglia, hippocampus
and cortex (between 2 and 5 fmol/mm3). Other brain structures,
including the cerebellum, brainstem and white matter, display
even lower NET densities.
With respect to in vivo imaging of the human brain, the gradual
decrease of binding among the cortical and sub-cortical structures
should not, however, mislead us regarding the usefulness of these
structures inmolecular imaging studies on the human brain. As the
LC’s volume is only 0.10–0.15 cm3, the LC would not be a useful
imaging target in functional neuroimaging studies. Furthermore,
as we have shown that the cortical uptake of the ligand is cell layer
speciﬁc, the cortex per se does not seem to be an appropriate
imaging target either. The thalamus (volume: 8.1–9.1 cm3), a
prime projection structure of LC, however, may be a prospective
candidate of a target region in PET studies (Tuohy et al., 2004;
Andrews et al., 1997).
4.3. NET distribution in AD brains
Classical histochemical and immunohistochemical techniques
showedamarkeddecrease inNETpositivecells in theLCofADbrains
as compared to control brains. Furthermore, they have justiﬁed the
diagnosis by displaying post-mortem histological and morphologi-
cal signs of AD in the diseased brains (Thal and Braak, 2005).
In line with earlier studies (Tejani-Butt et al., 1993; Szot et al.,
2000, 2006; Haglund et al., 2006) there is a marked (though non-
signiﬁcant, p = 0.0735) decrease in NET densities in the LC in AD
patients as compared to age-matched controls. This observation,
however, needs a technical comment. The determination of the
exact location of the LC in diseased brains was not possible, as due
to the loss of neurons neither the classical histological techniques
nor the autoradiographic investigation was able to outline the
borders of the LC. The operational deﬁnition of the LC in these cases
was based upon the macroanatomical landmarks, including the
midline and the contours of the brain stem. Should one be able toﬁnd the appropriate borders of the LC in the advanced AD cases,
one would expect to have a better signiﬁcance value regarding the
loss of NET densities in AD as compared to age-matched control
material.
In the thalamus we found a signiﬁcantly lower NET density in
AD than in control brains (p = 0.0353), whereas nomarked changes
were observed in other brain structures between AD and control
brains. In comparison with the ﬁnding in the LC, this fact may
underline the importance of reliable anatomical boundaries, used
for the determination of the region of interest. The relatively large
thalamus (8–9 cm3; see above) may indeed serve as a region of
interest for both post-mortem and in vivo studies on the
determination of NET densities in AD vs. control brains.
There was a signiﬁcant negative correlation (p < 0.05) between
the Braak grades of the AD brains and NET densities, as measured
by speciﬁc binding values, in both the LC and the thalamus,
indicating that the progress of disease entails a steady and gradual
loss of NET neurons in these structures.
4.4. The potential of (S,S)-[18F]FMeNER-D2 as a PET imaging
biomarker
Recent molecular imaging studies by our group have demon-
strated the usefulness of (S,S)-[18F]FMeNER-D2 as a PET radi-
oligand for NET in the non-human primate brain and the human
brain (Takano et al., 2008a,b,c, 2009a,b). The investigations were
performed in healthy animals and human subjects. The present
investigations aimed at exploring the ligand’s potential use in
diseased human brains, with special regard to AD, as an early
molecular imaging biomarkers.
In the present context, a number of considerations should be
carefully explored and deliberated. A major issue is the volumes of
the target structures in the brain. Asmentioned, the primary target
structure, the LC, is in the range of 0.1 cm3. It can be visualisedwith
a high resolution research scanner (HRRT), as shown by our group
(Takano et al., 2008a,b,c). However, this approach can hardly be
used in routine clinical diagnostic practice. The thalamus, having a
signiﬁcantly larger volume (approximately 9 cm3), appears to be a
more adequate target structure in routine PET investigations in this
regard. In healthy human brain the NET density differences
between the LC and thalamus are 10-fold and this appears to be
sufﬁcient for imaging studies in healthy volunteers with an
appropriate research scanner as demonstrated by our former in
vivo PET studies (Takano et al., 2008a,b,c). The conundrum is
whether in AD patients, wherein both the volume of these target
structures and the density of NET heavily decreases, the successful
imaging of NET is still possible with the present radioligand and
imaging approach.
A further consideration should concern the relationship
between NET density in the human brain and the afﬁnity of
(S,S)-[18F]FMeNER-D2. According to the herewith presented data,
the density of NET in the thalamus is about 4.2 nM (Table 1), while
the afﬁnity of (S,S)-[18F]FMeNER-D2 is around 3.6 nM, giving rise to
a Bmax/KD ratio of 1.17. In diagnostic imaging practice, for
successful imaging an in vitro Bmax/KD ratio of at least 3 or higher
is usually sought. Despite this expectation (S,S)-[18F]FMeNER-D2
has proven to be the only acceptable PET ligand of NET until today
(Takano et al., 2008a,b,c, 2009a,b). To satisfactorily answer the
question whether the ligand may serve as a useful molecular
imaging biomarker for early identiﬁcation of AD and for monitor-
ing disease progression, further studies are warranted.
5. Summary and conclusion
There are signiﬁcant decreases in NET density in the LC and the
thalamus in AD brains as compared to age-matched controls. In
B. Gulya´s et al. / Neurochemistry International 56 (2010) 789–798 797both cases, the decreases negatively correlate with increasing
Braak grades and, thus, can serve as a biomarker of disease.
Whereas the LC is a small nucleus in the human brain, the human
thalamus, the primary projection structure of LC, due to its volume
and the hereby demonstrated signiﬁcant decrease in NET densities
in AD brains as compared to age-matched control brains,may serve
as a target region in functional neuroimaging studies with PET for
the detection of changes in NET densities in suspected AD patients.
Finally, the present data warrant further investigations regarding
the possible use of (S,S)-[18F]FMeNER-D2 as a molecular imaging
biomarker in AD.
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